🔴 AIM ImmunoTech is trading 5% down today after a $3.8 million Q2 net loss

AIM ImmunoTech is trading at $0.27, down -5.05%, after second-quarter results showed a $3.8 million net loss.

• The company reported $9.9 million in cash and completed DURIPANC enrollment.
• Investors may be weighing the wait for pancreatic-cancer data, with key readouts expected in 2027, against continued cash burn.
• Its ATM equity program will end August 15, 2026, limiting that financing channel.